Literature DB >> 19289520

Quasiexperimental study of the effects of antibiotic use, gastric acid-suppressive agents, and infection control practices on the incidence of Clostridium difficile-associated diarrhea in hospitalized patients.

Mamoon A Aldeyab1, Stephan Harbarth, Nathalie Vernaz, Mary P Kearney, Michael G Scott, Chris Funston, Karen Savage, Denise Kelly, Motasem A Aldiab, James C McElnay.   

Abstract

The objective of this study was to evaluate the effects of antimicrobial drug use, gastric acid-suppressive agent use, and infection control practices on the incidence of Clostridium difficile-associated diarrhea (CDAD) in a 426-bed general teaching hospital in Northern Ireland. The study was retrospective and ecological in design. A multivariate autoregressive integrated moving average (time-series analysis) model was built to relate CDAD incidence with antibiotic use, gastric acid-suppressive agent use, and infection control practices within the hospital over a 5-year period (February 2002 to March 2007). The findings of this study showed that temporal variation in CDAD incidence followed temporal variations in expanded-spectrum cephalosporin use (average delay = 2 months; variation of CDAD incidence = 0.01/100 bed-days), broad-spectrum cephalosporin use (average delay = 2 months; variation of CDAD incidence = 0.02/100 bed-days), fluoroquinolone use (average delay = 3 months; variation of CDAD incidence = 0.004/100 bed-days), amoxicillin-clavulanic acid use (average delay = 1 month; variation of CDAD incidence = 0.002/100 bed-days), and macrolide use (average delay = 5 months; variation of CDAD incidence = 0.002/100 bed-days). Temporal relationships were also observed between CDAD incidence and use of histamine-2 receptor antagonists (H2RAs; average delay = 1 month; variation of CDAD incidence = 0.001/100 bed-days). The model explained 78% of the variance in the monthly incidence of CDAD. The findings of this study highlight a temporal relationship between certain classes of antibiotics, H2RAs, and CDAD incidence. The results of this research can help hospitals to set priorities for restricting the use of specific antibiotic classes, based on the size-effect of each class and the delay necessary to observe an effect.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19289520      PMCID: PMC2681522          DOI: 10.1128/AAC.01214-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Clarithromycin appears to be linked with Clostridium difficile-associated diarrhoea in the elderly.

Authors:  A Guyot; M D Rawlins; S P Barrett
Journal:  J Antimicrob Chemother       Date:  2000-10       Impact factor: 5.790

Review 2.  Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review.

Authors:  Claudia Thomas; Mark Stevenson; Thomas V Riley
Journal:  J Antimicrob Chemother       Date:  2003-05-13       Impact factor: 5.790

3.  Effectiveness of environmental and infection control programs to reduce transmission of Clostridium difficile.

Authors:  Anucha Apisarnthanarak; Jeanne E Zack; Jennie L Mayfield; Janet Freeman; William M Dunne; J Russel Little; Linda M Mundy; Victoria J Fraser
Journal:  Clin Infect Dis       Date:  2004-08-15       Impact factor: 9.079

4.  Clarithromycin and pseudomembranous enterocolitis.

Authors:  C P Braegger; D Nadal
Journal:  Lancet       Date:  1994-01-22       Impact factor: 79.321

Review 5.  Antimicrobial resistance in hospital organisms and its relation to antibiotic use.

Authors:  J E McGowan
Journal:  Rev Infect Dis       Date:  1983 Nov-Dec

6.  Factors associated with nosocomial diarrhea and Clostridium difficile-associated disease on the adult wards of an urban tertiary care hospital.

Authors:  M J Schwaber; A Simhon; C Block; V Roval; N Ferderber; M Shapiro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-01       Impact factor: 3.267

7.  Clostridium difficile-associated diarrhoea in hospitalised patients.

Authors:  F A Al-Eidan; J C McElnay; M G Scott; M P Kearney
Journal:  J Clin Pharm Ther       Date:  2000-04       Impact factor: 2.512

8.  Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies.

Authors:  Sandra Dial; Khalid Alrasadi; Chantal Manoukian; Allen Huang; Dick Menzies
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

9.  Risk factors for Clostridium difficile colonisation and toxin production.

Authors:  John M Starr; Heather Martin; Jodie McCoubrey; Gavin Gibson; Ian R Poxton
Journal:  Age Ageing       Date:  2003-11       Impact factor: 10.668

10.  Fluoroquinolone use and Clostridium difficile-associated diarrhea.

Authors:  Margaret E McCusker; Anthony D Harris; Eli Perencevich; Mary-Claire Roghmann
Journal:  Emerg Infect Dis       Date:  2003-06       Impact factor: 6.883

View more
  17 in total

1.  Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage.

Authors:  James A McKinnell; Danielle F Kunz; Eric Chamot; Mukesh Patel; Rhett M Shirley; Stephen A Moser; John W Baddley; Peter G Pappas; Loren G Miller
Journal:  Infect Control Hosp Epidemiol       Date:  2012-05-14       Impact factor: 3.254

2.  A point prevalence survey of antibiotic prescriptions: benchmarking and patterns of use.

Authors:  Mamoon A Aldeyab; Mary P Kearney; James C McElnay; Fidelma A Magee; Geraldine Conlon; Dianne Gill; Peter Davey; Arno Muller; Herman Goossens; Michael G Scott
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

3.  Relationship between antibiotic consumption and Clostridium difficile-associated diarrhea: an epidemiological note.

Authors:  Klaus Kaier; Uwe Frank
Journal:  Antimicrob Agents Chemother       Date:  2009-10       Impact factor: 5.191

4.  Association between Clostridium difficile infection and antimicrobial usage in a large group of English hospitals.

Authors:  Joao B Pereira; Tracey M Farragher; Mary P Tully; Jonathan Jonathan Cooke
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

5.  Seasonal variations in Clostridium difficile infections are associated with influenza and respiratory syncytial virus activity independently of antibiotic prescriptions: a time series analysis in Quebec, Canada.

Authors:  Rodica Gilca; Elise Fortin; Charles Frenette; Yves Longtin; Marie Gourdeau
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

6.  The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings.

Authors:  Mamoon A Aldeyab; Stephan Harbarth; Nathalie Vernaz; Mary P Kearney; Michael G Scott; Feras W Darwish Elhajji; Motasem A Aldiab; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

7.  Stronger correlation between antibiotic use and the incidence of Clostridium difficile determined by culture results instead of faecal toxin detection only.

Authors:  D Mertz; R Frei; H Plagge; M Battegay; A F Widmer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-08-13       Impact factor: 3.267

8.  The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?

Authors:  Justyna Bien; Vindhya Palagani; Przemyslaw Bozko
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

9.  Reduction in the incidence of hospital-acquired MRSA following the introduction of a chlorine dioxide 275 ppm based disinfecting agent in a district general hospital.

Authors:  Geraldine Conlon-Bingham; Mamoon Aldeyab; Mary P Kearney; Michael G Scott; Naomi Baldwin; James C McElnay
Journal:  Eur J Hosp Pharm       Date:  2015-08-19

10.  Clostridium: transmission difficile?

Authors:  Stephan Harbarth; Matthew H Samore
Journal:  PLoS Med       Date:  2012-02-07       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.